<DOC>
	<DOCNO>NCT00665600</DOCNO>
	<brief_summary>To investigate efficacy safety repeat dose Levalbuterol 6 week treatment COPD .</brief_summary>
	<brief_title>Efficacy Safety Levalbuterol Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>This study multi-center , randomize , double-blind , placebo active control , parallel-group study adult subject COPD . Approximately 250 subject enrol randomize least 200 subject . Study participation consist total six study visit nine week subject . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Male female subject must least great equal 35 year age time consent . Subjects must preestablished primary clinical diagnosis COPD . Subjects must baseline FEV1 le equal 65 % Subjects must predict &gt; 0.70 Liter subject take steroid ( inhale , oral , nasal ) , shortacting xanthine , leukotrienes , dose must stable 30 day Subjects must FEV1/forced vital capacity ( FVC ) less equal 70 % Subjects must great equal 15 packyear smoke history Subjects must baseline medical research council ( MRC ) dyspnea scale score great equal 2 Regular use prescribe therapy control COPD symptoms 3 month prior study entry . No COPD exacerbation require emergency room visit , hospital admission intensive outpatient therapy within 1 month prior study entry Females pregnant lactating . Concurrent requirement oxygen therapy Known history asthma , chronic respiratory disease COPD ( include chronic bronchitis emphysema ) . Diagnosis cancer within 5 year prior study entry exception nonmelanoma skin cancer . Lung resection one full lobe . Use intravenous , intraarticular intramuscular corticosteroid within 30 day study entry History upper low respiratory infection within 14 day study entry . Participation investigational drug study within 30 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Chronic Emphysema</keyword>
</DOC>